

Translation

Notice: This document is an excerpt translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

November 9, 2023

FOR IMMEDIATE RELEASE

Company name: H.U. Group Holdings, Inc.
Representative: Shigekazu Takeuchi, Chairman,
President and Group CEO
Securities code: 4544 Prime Market, Tokyo Stock
Exchange
Contact: Atsuko Murakami, Executive
Officer and CFO
Telephone No.: +81-3-6279-0926

Notice Concerning Revisions to Full-Year Consolidated Earnings Forecasts

H.U. Group Holdings, Inc. (the "Company") hereby announces that in light of the most recent operating trends, the Company revised its full-year consolidated earnings forecasts for the fiscal year ending March 31, 2024, as initially announced on May 12, 2023. Details are as follows.

1. Revisions to full-year consolidated earnings forecast for the fiscal year ending March 31, 2024 (April 1, 2023 – March 31, 2024)

| | Net sales (millions of yen) | Operating profit (millions of yen) | Ordinary profit (millions of yen) | Profit attributable to owners of parent (millions of yen) | Earnings per share (yen) | (Reference) EBITDA ¹ (millions of yen) |
|--|-----------------------------------|---|--|--|--------------------------------|--|
| Previous Forecast (A) | 245,000 | 14,000 | 12,000 | 6,000 | 105.43 | 36,000 |
| Revised forecast (B) | 240,000 | 4,000 | 2,500 | 0 | 0.00 | 25,000 |
| Change (B - A) | -5,000 | -10,000 | -9,500 | -6,000 | -105.43 | -11,000 |
| Change (%) | -2.0 | -71.4 | -79.2 | -100.0 | -100.0 | -30.6 |
| (Reference) Results for the previous fiscal year (Fiscal year ended March 31, 2023) | 260,908 | 23,381 | 22,010 | 15,676 | 275.52 | 43,076 |

1. EBITDA = Operating profit + Depreciation + Amortization of goodwill

2. Reasons for revisions

The Company initially anticipated a certain level of demand for COVID-19-related tests at the beginning of the fiscal year. However, with COVID-19 being reclassified to Category 5 Infectious Disease under the Infectious Disease Control Law, the demand for related tests significantly decreased. The number of tests within the base business, which was expected to gradually return to normal, has experienced a slower-than-expected recovery and is currently below the initial expectations.

Additionally, the impact of addressing reporting delays for general testing at Akiruno Central Laboratories

(in AkirunoCube) that occurred in the second quarter, has also been factored into account of the revision.

As a result of these considerations, the Company revised its full-year consolidated earnings forecasts as outlined above.

3. Dividend Forecast

There is no change to the amount of the dividend forecast per share (Interim: 62 yen, Year-end: 63 yen, and Annual: 125 yen) announced on May 12, 2023.

The earnings forecasts above have been prepared based on information available as of the date on which this material was announced. Actual results may differ due to a variety of factors going forward.

End